Safety of exenatide once weekly for 52weeks in Japanese patients with type 2 diabetes mellitus

Journal of Diabetes Investigation

Volumn 4, Issue 2, 2013, Pages 182-189

  Onishi, Yukiko ^a   Koshiyama, Hiroyuki ^b   Imaoka, Takeshi ^c   Haber, Harry ^d   Scism Bacon, Jamie ^d   Boardman, Marilyn K ^e  

^a INSTITUTE FOR ADULT DISEASES   (Japan)

^b Kitano Hospital   (Japan)

^c Eli Lilly Japan   (Japan)

^d SYNEOS HEALTH   (United States)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

Blood glucose; Exenatide; Japanese

Indexed keywords

EXENDIN 4; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ABDOMINAL DISCOMFORT; ADULT; ANTIBODY TITER; ARTICLE; BRONCHITIS; CELLULITIS; CLINICAL TRIAL; CONSTIPATION; DECREASED APPETITE; DIABETIC RETINOPATHY; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PRURITUS; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; TINEA PEDIS; UPPER ABDOMINAL PAIN; VOMITING; WEIGHT REDUCTION;

EID: 84878361342     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12000     Document Type: Article

References (18)

1. Wild S, Roglic G, Green A, etal. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
2. Neville SE, Boye KS, Montgomery WS, etal. Diabetes in Japan: a review of disease burden and approaches to treatment. Diabetes Metab Res Rev 2009; 25: 705-716.
3. Kobayashi M, Yamazaki K, Hirao K, etal. The status of diabetes control and antidiabetic drug therapy in Japan-a cross-sectional survey of 17, 000 patients with diabetes mellitus (JDDM 1). Diabetes Res Clin Pract 2006; 73: 198-204.
4. Arai K, Matoba K, Hirao K, etal. Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15, 652 patients. Endocr J 2010; 57: 499-507.
5. Heine RJ. Role of sulfonylureas in non-insulin dependent diabetes mellitus: part II -'The cons'. Horm Metab Res 1996; 28: 522-526.
6. Kadowaki T, Namba M, Imaoka T, etal. Improved glycemic control and reduced bodyweight with exenatide: a double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24weeks. J Diabetes Invest 2011; 2: 210-217.
7. Buse JB, Henry RR, Han J, etal. Effects of exenatide (exendin-4) on glycemic control over 30weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-2635.
8. Kendall DM, Riddle MC, Rosenstock J, etal. Effects of exenatide (exendin-4) on glycemic control over 30weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-1091.
9. DeFronzo RA, Ratner RE, Han J, etal. Effects of exenatide (exendin-4) on glycemic control and weight over 30weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100.
10. European Medicines Agency. Bydureon: EPAR - Summary for the Public. [Internet] [Updated 2011 May; accessed on 2012, February 14]. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002020/human_med_001457.jsp&mid=WC0b01ac058001d124&murl=menus/medicines/medicines.jsp&jsenabled=true.
11. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. [Internet] [Updated 2012 July; accessed on 2012, July 13]. Available at: http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=022200&TABLE1=OB_Rx
12. Drucker DJ, Buse JB, Taylor K, etal. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240-1250.
13. Blevins T, Pullman J, Malloy J, etal. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab 2011; 96: 1301-1310.
14. Ji L, Onishi Y, Chul Ahn CW, etal. Efficacy and Safety of Exenatide Once Weekly Versus Exenatide Twice Daily in Asian Patients with Type 2 Diabetes. International Diabetes Federation. Dubia, Saudia Arabia. December 5, 2011: P1144. [Internet] [accessed on 2012, July 20] Available at: http://conference2.idf.org/dubai2011/CM.NET.WebUI/CM.NET.webUI.SCPR/SCPRfunctiondetail.aspx?confID=05000000-0000-0000-0000-000000000001&sesID=05000000-0000-0000-0000-000000000509&absID=07000000-0000-0000-0000-000000003708
15. Fineman MS, Mace KF, Diamant M, etal. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab, 2012; 14: 546-554.
16. Macconell L, Brown C, Gurney K, etal. Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials. Diabetes Metab Syndr Obes 2012; 5: 29-41.
17. Diamant M, Van Gaal L, Stranks S, etal. Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84weeks. Diabetes Care 2012; 35: 683-689.
18. Buse JB, Drucker DJ, Taylor KL, etal. DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52weeks. Diabetes Care 2010; 33: 1255-1261.